ANTI-VEGF DRUGS AS THE 2009 FIRST-LINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA

被引:91
|
作者
Cohen, Salomon Y. [1 ,2 ]
机构
[1] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France
[2] Univ Paris 07, Dept Ophthalmol, AP HP, Hop Lariboisiere, Paris, France
关键词
myopia; choroidal neovascularization; bevacizumab; ranibizumab; antivascular endothelial growth factor; INTRAVITREAL BEVACIZUMAB AVASTIN; COMBINED PHOTODYNAMIC THERAPY; OPTICAL COHERENCE TOMOGRAPHY; TRANSPUPILLARY THERMOTHERAPY; LASER PHOTOCOAGULATION; SURGICAL REMOVAL; NATURAL-HISTORY; VERTEPORFIN; AGE; SECONDARY;
D O I
10.1097/IAE.0b013e3181b1bb1a
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-term effectiveness has been disappointing. Antivascular enclothelial growth factor (anti-VEGF) drugs are now widely used not only to treat choroidal neovascularization in AMD but also for choroidal neovascularization in other conditions. This review summarizes the data supplied by published case series studies about anti-VEGF therapy in mCNV. Methods: Analysis of the current literature allowed discussion of the optimal parameters for mCNV treatment by anti-VEGF, including the choice of anti-VEGF drug, its dose, the treatment protocol, and indications for retreatment. Results: To date, the results of intravitreal bevacizumab or ranibizumab for mCNV have been reported in at least 14 studies, but they were all pilot, monocentric, and noncomparative case series. Nevertheless, they provided useful information on >250 patients and showed similar results, with significant improvement of visual acuity and an excellent safety profile. Conclusion: Shifting from one treatment to another is always difficult in the absence of prospective and controlled comparative studies. However, in 2009, intravitreal ranibizumab or bevacizumab may be considered as first-line therapy for sub- and juxtafoveal mCNV for three reasons: the safety of anti-VEGF drugs and intravitreal injection procedures; the disappointing long-term results of other therapies, including verteporfin treatment; and the excellent convergent results of anti-VEGF therapy in all pilot studies. RETINA 29:1062-1066, 2009
引用
收藏
页码:1062 / 1066
页数:5
相关论文
共 50 条
  • [21] EVALUATION OF CHOROIDAL NEOVASCULARIZATION BEFORE AND AFTER ANTI-VEGF THERAPY USING OCT ANGIOGRAPHY
    Chanana, B.
    Bharti, S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2017, 27 (02) : E66 - E66
  • [22] Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
    Dimopoulos, Spyridon
    Leitritz, Martin Alexander
    Ziemssen, Focke
    Voykov, Bogomil
    Bartz-Schmidt, Karl Ulrich
    Gelisken, Faik
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 1537 - 1541
  • [23] INTRAVITREAL ANTI-VEGF VERSUS PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION
    Yoon, Jong Uk
    Byun, Yeo Jue
    Koh, Hyoung Jun
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (03): : 418 - 424
  • [24] Suppression of Murine Choroidal Neovascularization After Systemic Administration of a Targeted Anti-VEGF Therapy
    Cleland, Jeffrey L.
    Sharma, Rishi
    Appiani, Santiago
    Prater, Justin
    Spiga, M. Grazia
    Culp, David
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [25] Development of Choroidal Neovascularization in the Second Eye of Neovascular AMD Patients Treated with Anti-VEGF Drugs
    Abraham, Jonah
    Elman, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [26] Corneal Neovascularization: An Anti-VEGF Therapy Review
    Chang, Jin-Hong
    Garg, Nitin K.
    Lunde, Elisa
    Han, Kyu-Yeon
    Jain, Sandeep
    Azar, Dimitri T.
    SURVEY OF OPHTHALMOLOGY, 2012, 57 (05) : 415 - 429
  • [27] Choroidal neovascularization secondary to pathological myopia—macular Bruch membrane defects as prognostic factor to anti-VEGF treatment
    João Coelho
    André Ferreira
    Ana Carolina Abreu
    Sílvia Monteiro
    Maria João Furtado
    Miguel Gomes
    Miguel Lume
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259 : 2679 - 2686
  • [28] Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia
    Virgili, Gianni
    Varano, Monica
    Giacomelli, Giovanni
    Arena, Maria Chiara
    Tedeschi, Massimiliano
    Pascarella, Antonella
    Catalano, Susanna
    Menchini, Ugo
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (01) : 77 - 82
  • [29] Intravitreal Anti-VEGF Therapy for Choroidal Neovascularization-Associated with Best Vitelliform Macular Dystrophy
    Grigorian, Florin
    Vasconcelos, Huber Martins
    Bailey, Steven T.
    Lujan, Brandon J.
    Campbell, J. Peter
    Lin, Phoebe
    Weleber, Richard G.
    Pennesi, Mark E.
    Yang, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [30] Acute Syphilitic Posterior Placoid Chorioretinitis With Subfoveal Choroidal Neovascularization Managed With Anti-VEGF Therapy
    Wai, Karen M.
    Gong, Dan
    Rodriguez, Marianeli
    Cunningham, Emmett T., Jr.
    Vavvas, Demetrios G.
    Eliott, Dean
    JOURNAL OF VITREORETINAL DISEASES, 2022, 6 (03) : 246 - 250